Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study

• Main Authors: Charlotte Bellier (Author), Laurence Gladieff (Author), Fanny Le Du (Author), Dominique Berton (Author), Charlotte Bonnard (Author), Delphine Suau (Author), Anne-Céline Richard (Author), Ophélie Brenner (Author), Amir Lahouegue (Author), Gilles Freyer (Author), Anne Floquet (Author), Sophie Frank (Author), Maria Kfoury (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2023-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Olaparib, a poly(ADP-ribose) polymerase inhibitor, was approved by the European Commission in June 2019, following the results of the SOLO-1/GOG 3004 trial as maintenance monotherapy in adult patients with BRCA-mutated epithelial ovarian cancer. Objective This study aimed to prov...